Interview: Francesco di Marco – General Manager, Amgen Italy
Francesco di Marco, General Manager for Amgen Italy, shares his view on the state of the Italian pharmaceutical sector, the turnaround the company has made in the country, and what…
Shionogi Europe is a new healthcare company, launched approximately 130 years after the organisation was founded (1878) by Gisaburo Shiono SR. in Doshomachi, Osaka, Japan. The company has grown to become a major research-driven pharmaceutical company dedicated to placing the highest value on patient care.
We are guided by a simple but powerful principle: follow the needs of the patient and the community that surrounds them. This means ensuring that the real-life challenges patients face everyday remain the primary purpose behind R&D, which we believe is a more encouraging way to create clinically-meaningful therapies.
Products and services
We are a research-led organisation, defined by a distinct openness and close partnership approach to creating vaccines and medicines spanning pain, infectious diseases, metabolic disorders, women’s health and oncology.
Our development approach goes hand in hand with the collaborative drug discovery process at the heart of Shionogi. We have an impressive track record of fostering long-term industry partnerships built on trust and a mutual ambition to develop innovative medicines that address unmet medical needs. In 1998 Shionogi licensed one of its new molecules, which later became Crestor (rosuvastatin) to AstraZeneca and still markets this product in Japan today. Other important discoveries include Tivicay and Triumeq, new anti-HIV drugs now marketed by ViiV Healthcare.
Contact
Address: 33 Kingsway, London WC2B 6UF
Tel: +44-203-053-4200
Web: www.shionogi.eu
Francesco di Marco, General Manager for Amgen Italy, shares his view on the state of the Italian pharmaceutical sector, the turnaround the company has made in the country, and what…
Galderma Italy was a founding European affiliate for the company and has seen incredible growth in the past two decades. Managing Director Bernat Albinyana discusses the affiliate’s performance, its business…
Dr. Ermano Buratti, General Manager for Astellas Pharma in Italy, discusses the company’s evolution as it enters its second decade, the importance of partnering with the government on reimbursement, the…
In 2008 Focus Reports interviewed Mr. Federico Seghi Recli as he prepared to transform Molteni Farmaceutici into an International specialty pharma company. Today we catch up on the progress, investments…
The General Manager for Eli Lilly Italy, discusses how the company’s continuous commitment to Italy has benefited the organization, the promise the country holds if certain barriers can be overcome, and how Lilly’s…
The CEO of MSD Italy discusses the company’s promising pipeline, its plans to realize growth through the launch of innovative new drugs in 2016, the paths towards a sustainable healthcare…
The MD of the Spanish Chamber of Commerce in Italy takes stock of the prevailing business winds between the two countries as both economies complete their emergence from the shadow of…
Massimo Visentin, Country Leader for Pfizer Italy, discusses the company’s remarkable success in 2015, his hopes and ambitions for the new year, and the need of the industry and Pfizer…
Prof. Luigi Naldini, Director of TIGET, discusses the success of the institute and the groundbreaking partnerships it has formed with the pharmaceutical industry, as well as his ambitions for TIGET…
Pasquale Frega, General Manager for Celgene Italy, discusses the company’s rapid growth and imminent entry into immunology, the business and regulatory environment for innovators in the country and the characteristics…
Dr. Costas Piliounis discusses the importance of containing diabetes, the dampening effects budget ceilings have on companies’ performance and growth potential, as well as the positive influence which changes currently…
Chris Juliam, Managing Director for Takeda Italy, shares the strategy the company is pursuing in the country, the effects market-access issues are having on innovators and patients, and what new…
See our Cookie Privacy Policy Here
